Anticorps Polyclonal de lapin anti-NKRF

• Phare
• Validé par KD/KO

NKRF Polyclonal Antibody for WB, IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IF, IP, CoIP, ChIP, ELISA

Conjugaison

Non conjugué

Publications(5)

N° de cat : 14693-1-AP

Synonymes

ITBA4, NF kappa B repressing factor, NFKB repressing factor, NKRF, NRF, Protein ITBA4, Transcription factor NRF

---

Galerie de données de validation

• 

  WB analysis using 14693-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 14693-1-AP (NKRF antibody) at dilution of 1:15000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 14693-1-AP

  WB result of NKRF antibody (14693-1-AP; 1:10000; incubated at room temperature for 1.5 hours) with sh-Control and sh-NKRF transfected HEK-293 cells.

• 

  IP experiment of HeLa using 14693-1-AP

  IP result of anti-NKRF (IP:14693-1-AP, 4ug; Detection:14693-1-AP 1:10000) with HeLa cells lysate 840 ug.

---

Applications testées

• Résultats positifs en WB: cellules HeLa, cellules HEK-293, cellules HepG2, cellules Jurkat
• Résultats positifs en IP: cellules HeLa,

Dilution recommandée

• Western Blot (WB): WB : 1:5000-1:50000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 2 publications below
• WB: See 5 publications below
• IF: See 1 publications below
• CoIP: See 2 publications below
• ChIP: See 1 publications below

Informations sur le produit

14693-1-AP cible NKRF dans les applications de WB, IF, IP, CoIP, ChIP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: NKRF Protéine recombinante Ag6252
• Nom complet: NFKB repressing factor
• Masse moléculaire calculée: 78 kDa
• Poids moléculaire observé: 100 kDa
• Numéro d’acquisition GenBank: BC068514
• Symbole du gène: NKRF
• Identification du gène (NCBI): 55922
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

NKRF, also named as Protein ITBA4 or Transcription factor NRF, is a 690 amino acid protein, which contains one G-patch domain and one R3H domain. NKRF is Widely and constitutively expressed, with lower level in colon, peripheral blood lymphocytes, lung and kidney. NKRF interacts with a specific negative regulatory element (NRE) 5'-AATTCCTCTGA-3' to mediate transcriptional repression of certain NK-kappa-B responsive genes. NKRF is involved in the constitutive silencing of the IFN-β promoter, independently of the virus-induced signals, and in the inhibition of the basal and cytokine-induced iNOS promoter activity.

Publications

Species	Application	Title
human	WB	Mol Cancer; LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.; Authors - Xi Jin ; KD Validated
mouse	WB	Immunology; Down-regulation of miR-301a suppresses pro-inflammatory cytokines in TLR-triggered macrophages.; Authors - Huang Lisong L ; KD Validated
mouse	WB,IF,CoIP,ChIP	Adv Sci (Weinh); NKRF in Cardiac Fibroblasts Protects against Cardiac Remodeling Post-Myocardial Infarction via Human Antigen R; Authors - Chenghu Guo
human	WB	Int J Mol Sci; A1CF Binding to the p65 Interaction Site on NKRF Decreased IFN-β Expression and p65 Phosphorylation (Ser536) in Renal Carcinoma Cells; Authors - Yamin Liu
human	WB,CoIP	Dig Dis Sci; E3 Ubiquitination Ligase MYLIP Mediates the NKRF/SLC25A34 Axis to Suppress Malignant Progression in Colorectal Cancer; Authors - Chao Li

{{ptg:RelatedPrimaryAntibodies}}